Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate gvax and ipilimumab

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages 1-

  Santegoets, Saskia JAM ^a   Stam, Anita GM ^a   Lougheed, Sinéad M ^a   Gall, Helen ^a   Jooss, Karin ^b   Sacks, Natalie ^b   Hege, Kristen ^b   Lowy, Israel ^c   Scheper, Rik J ^a   Gerritsen, Winald R ^a   van den Eertwegh, Alfons JM ^a   de Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CELL GENESYS INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biomarker; Ipilimumab; Patient selection; Prostate GVAX; Survival prediction

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; MALE; MONOCYTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SUPPRESSOR CELL; TREATMENT RESPONSE;

EID: 84977103128     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-014-0031-3     Document Type: Article

References (53)

1. Drake CG Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010, 10:580-593.
2. Tannock IF, De WR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
4. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
5. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007, 30:825-830.
6. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007, 13:3883-3891.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
8. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, Macrae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003, 100:4712-4717.
9. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009, 69:609-615.
10. Hurwitz AA, Yu TF, Leach DR, Allison JP CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998, 95:10067-10071.
11. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:509-517.
12. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766.
13. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997, 3:483-490.
14. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166.
15. Della BS, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, Villa ML Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003, 89:1463-1472.
16. Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, Degos L, Dombret H, Toubert A, Rea D Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004, 18:1656-1661.
17. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD T cell profiling reveals high CD4 + CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013, 62:245-256.
18. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN Characterization of human blood dendritic cell subsets. Blood 2002, 100:4512-4520.
19. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal MR, Liu YJ Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283:1183-1186.
20. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, Hoffman SL, Weiss WR Plasmid vaccine expressing granulocytemacrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000, 165:3772-3781.
21. Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S, Chen SH In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 2004, 53:17-25.
22. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004, 64:6337-6343.
23. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factorbased antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
24. Suzuki J, Ricordi C, Chen Z Immune tolerance induction by integrating innate and adaptive immune regulators. Cell Transplant 2010, 19:253-268.
25. Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF, Roden RB CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1 + CD11b + myeloid cells. Cancer Res 2006, 66:6807-6815.
26. Liu Y, Yu Y, Yang S, Zeng B, Zhang Z, Jiao G, Zhang Y, Cai L, Yang R Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother 2009, 58:687-697.
27. van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC, Scheper RJ, Giaccone G, de Gruijl TD Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin Dev Immunol 2007, 2007:17315.
28. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008, 14:5884-5892.
29. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21:1232-1237.
30. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
31. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, Lin C, Pan Z, Yu Y, Jiang M, Zhou W, Cao X Human CD14 CTLA-4 regulatory dendritic cells suppress T cell response via CTLA-4-dependent IL-10 and IDO production in hepatocellular carcinoma. Hepatology 2014, 59:567-579.
32. Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A, Dozin B, Fontana V, Simone R, Mortara L, Mingari MC, Ferlazzo G, Pistillo MP CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 2010, 71:934-941.
33. Schakel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, Von KM, Rieber E 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002, 17:289-301.
34. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:35-45.
35. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB Immunosuppressive CD14 + HLA-DRlow/- monocytes in prostate cancer. Prostate 2010, 70:443-455.
36. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011, 60:1419-1430.
37. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4 (+) CD25 (+) Foxp3 (+) T cells. Gastroenterology 2008, 135:234-243.
38. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048.
39. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, et al Multipeptide immune response to cancer vaccine IMA901 after singledose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
40. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
41. Johansson CC, Mougiakakos D, Trocme E, II-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling R Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer 2010, 126:2682-2689.
42. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
43. Gorczyca W, Sun ZY, Cronin W, Li X, Mau S, Tugulea S Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol 2011, 103:221-266.
44. Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C, Kapanadze T, Compton K, Figg WD, Greten TF Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother 2012, 62:299-307.
45. Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2011, 23:170-176.
46. Weber J Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009, 58:823-830.
47. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598.
48. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006, 12:3394-3401.
49. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
50. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW, Schmitz J BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000, 165:6037-6046.
51. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.
52. Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber EP A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 1998, 28:4084-4093.
53. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014, 32:671-677.